Aldeyra submitted the single successful trial to the FDA over the summer and the agency accepted the resubmitted NDA for ...

Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...

Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a Phase ...

A new study from the University of Oklahoma suggests that small genetic differences in two proteins—previously known for ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...

Thyroid eye disease (TED), also known as Graves’ eye disease or Graves’ ophthalmopathy, is an inflammatory condition in people with thyroid disease. Treatment may include medication, eye drops, and ...

The decision comes after the committee recommended halting the studies for futility after reviewing interim data.

Thyroid eye disease (TED) is an inflammatory condition affecting those with thyroid disease. There is no cure, but effective management strategies exist. Thyroid eye disease, or Graves’ ophthalmopathy ...

Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.

When your vision is blurry, go to your eye doctor. Wash your hands before putting your contacts in. That's pretty much all there is to know about eye health, right? Think again. As with any other part ...

Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...